文献速递胸部肿瘤

比较氨柔比星与多西他赛治疗经治非小细胞肺癌患者的随机开放标签III期试验

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

日本32家机构纳入202例经1-2线化疗的非小细胞肺癌患者,随机接受氨柔比星(35 mg/m2,第1-3天,每3周)或多西他赛(60 mg/m2,第1天,每3周)。两组中位无进展生存期(3.6 vs 3.0个月,P=0.54)和总生存期(14.6 vs 13.5个月,P=0.86)相当;氨柔比星未显著改善主要终点无进展生存期。

要点

  • 氨柔比星组与多西他赛组中位PFS分别为3.6个月和3.0个月(P=0.54),无显著差异。
  • 两组中位OS分别为14.6个月和13.5个月(P=0.86),总缓解率分别为14.4%(14/97)和19.6%(19/97)(P=0.45)。
  • 两组疾病控制率均为55.7%;≥3级中性粒细胞减少发生率分别为82.7%和78.8%。

核心结论

  • 氨柔比星与多西他赛相比未显著改善经治非小细胞肺癌患者的主要终点无进展生存期。
  • 这是首个在经治非小细胞肺癌患者中比较氨柔比星与多西他赛的III期研究。

研究设计与样本

  • 随机、开放标签、III期试验,纳入日本经1或2线化疗后的非小细胞肺癌患者。
  • 2010年10月至2012年6月期间,32家机构共入组202例患者。
  • 患者随机接受氨柔比星35 mg/m2第1-3天每3周,或多西他赛60 mg/m2第1天每3周。
  • 结局包括无进展生存期、总生存期、肿瘤缓解和安全性。

主要发现

  • 氨柔比星组与多西他赛组中位无进展生存期分别为3.6个月和3.0个月(P=0.54)。
  • 氨柔比星组与多西他赛组中位总生存期分别为14.6个月和13.5个月(P=0.86)。
  • 氨柔比星组与多西他赛组总缓解率分别为14.4%(14/97)和19.6%(19/97)(P=0.45)。
  • 两组疾病控制率均为55.7%。
  • 所有患者均发生不良事件;氨柔比星组与多西他赛组≥3级中性粒细胞减少发生率分别为82.7%和78.8%,≥3级白细胞减少分别为63.3%和70.7%,≥3级发热性中性粒细胞减少分别为13.3%和18.2%。

关键数值与推荐

  • 氨柔比星给药方案:35 mg/m2,第1-3天,每3周。
  • 多西他赛给药方案:60 mg/m2,第1天,每3周。
  • 主要终点无进展生存期:氨柔比星组3.6个月 vs 多西他赛组3.0个月(P=0.54)。
  • 总生存期:氨柔比星组14.6个月 vs 多西他赛组13.5个月(P=0.86)。
  • 总缓解率:氨柔比星组14.4%(14/97) vs 多西他赛组19.6%(19/97)(P=0.45)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a standard treatment for NSCLC, have been reported. PATIENTS AND METHODS: We conducted a randomized phase III trial of Japanese NSCLC patients after one or two chemotherapy regimens. Patients were randomized to amrubicin (35 mg/m2 on days 1-3 every 3 weeks) or docetaxel (60 mg/m2 on day 1 every 3 weeks). Outcomes included progression-free survival, overall survival, tumor responses, and safety. RESULTS: Between October 2010 and June 2012, 202 patients were enrolled across 32 institutions. Median progression-free survival (3.6 versus 3.0 months; P = 0.54) and overall survival (14.6 versus 13.5 months; P = 0.86) were comparable in the amrubicin and docetaxel groups, respectively. The overall response rate was 14.4% (14/97) and 19.6% (19/97) in the amrubicin and docetaxel groups, respectively (P = 0.45). The disease control rate was 55.7% in both groups. Adverse events occurred in all patients, and included grade ≥3 neutropenia occurred in 82.7% and 78.8% of patients in the amrubicin and docetaxel groups, respectively, grade ≥3 leukopenia occurred in 63.3% and 70.7%, and grade ≥3 febrile neutropenia occurred in 13.3% and 18.2% of patients in the amrubicin and docetaxel groups, respectively. Of eight cardiac-related events in the amrubicin group, three were considered related to amrubicin and resolved without treatment discontinuation. CONCLUSIONS: This was the first phase III study to compare amrubicin and docetaxel in patients with pretreated NSCLC. Amrubicin did not significantly improve the primary endpoint of PFS compared with docetaxel. CLINICAL TRIAL REGISTRATION: NCT01207011 (ClinicalTrials.gov).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Yoshioka H, Katakami N, Okamoto H, et al. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2017. PMID: 28426104. doi:10.1093/annonc/mdw621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。